Stock Movers Hims & Hers Surges on Novo Obesity Deal; Live Nation Rises; Powerus & Aureus Greenway to Merge
Mar 9, 2026
A roundup of a surprise weight-loss drug deal that sent Hims & Hers stock higher. Coverage of Live Nation's reported $200 million settlement with the DOJ and what it could mean for ticketing. A merger in the drone and autonomous systems space involving Powerus and Aureus Greenway and plans for a NASDAQ roll-up.
AI Snips
Chapters
Transcript
Episode notes
Hims & Hers Ends Public Feud With Novo Nordisk
- Hims & Hers reversed course and struck a deal with Novo Nordisk to sell its weight-loss drugs on Hims' platform.
- Novo had sued Hims in February over copycat Wagovi and earlier shelved a similar deal after Hims marketed competing compounded drugs, making the partnership a notable turnaround.
Competitive Pressures Reshape Weight Loss Drug Market
- The weight-loss drug market is being squeezed by cheaper compounded copies and stronger rivals like Eli Lilly's Wegovy competitor.
- Hims shares jumped about 7% on the news but remain down roughly 51% year-to-date, highlighting market skepticism despite the deal.
Live Nation Reaches Framework With DOJ
- Live Nation reportedly reached a settlement framework with the DOJ to resolve its monopoly lawsuit, including $200 million in damages to participating states.
- The deal still needs a judge's approval and some state AGs like New York's Letitia James may continue litigation, so the outcome and consumer impact remain uncertain.